Back to news

PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors

Globe Newswire•20/11/2026•10:30 ET
0

Key Highlights

  • ➤48% ORR and 10.4-month median response duration in 65 ovarian cancer patients
  • ➤36% ORR and 8.1-month median response duration across 168 evaluable patients
  • ➤PMV plans rezatapopt NDA submission for ovarian cancer in Q1 2027
  • ➤Rezatapopt showed confirmed responses across eight TP53 Y220C-mutated tumor types
  • ➤Eleven patients, or 6%, discontinued treatment because of treatment-related adverse events

Expert Statements

Alison M. Schram, Medical Oncologist at Memorial Sloan Kettering Cancer Center and PYNNACLE Study Investigator

“Patients with platinum-resistant ovarian cancer who have progressed on standard therapies have few treatment options”

Alison M. Schram, Medical Oncologist at Memorial Sloan Kettering Cancer Center and PYNNACLE Study Investigator

“In this heavily pretreated population, nearly half of patients with platinum-resistant/refractory ovarian cancer responded to rezatapopt, and those responses lasted a median of more than 10 months.”

Alison M. Schram, Medical Oncologist at Memorial Sloan Kettering Cancer Center and PYNNACLE Study Investigator

“These results support rezatapopt as a potential new targeted option for patients whose tumors harbor a TP53 Y220C mutation.”

Deepika Jalota, Chief Development Officer of PMV Pharma

“The primary analysis reinforces the consistent, durable activity of rezatapopt in patients with platinum-resistant ovarian cancer that has been observed throughout the study”

Deepika Jalota, Chief Development Officer of PMV Pharma

“For patients who have endured multiple rounds of chemotherapy, rezatapopt has the potential to be a single-agent, chemotherapy-free, once-daily oral option they can take at home.”

Deepika Jalota, Chief Development Officer of PMV Pharma

“We expect to submit our NDA for accelerated approval in the first quarter of 2027.”

* 48% confirmed overall response rate (ORR) with a 10.4-month median duration of response in the primary analysis population of 65 patients with platinum-resistant/refractory ovarian cancer

* 36% ORR with an 8.1-month median duration of response across all cohorts in the overall population of 168 evaluable patients

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in